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Background 
This interim guidance has been developed based on the advice issued by the Strategic Advisory Group of Experts on 
Immunization (SAGE) at its 5 January 2021 extraordinary meeting [1]. 
Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the 
reported interests can be found on the SAGE meeting website and SAGE Working Group website. 
 
Methods 
SAGE applies the principles of evidence-based medicine and has set in place a thorough methodological process for issuing or 
updating recommendations [2]. Specifically for COVID-19 vaccines, a detailed description of the methodological processes can 
be found in the SAGE evidence framework for COVID-19 vaccines. This framework is intended to offer guidance for considering 
data emerging from clinical trials in support of issuing vaccine-specific evidence-based recommendations [3]. 
 
General goal and strategy for the use of the mRNA vaccine BNT162b2 against COVID-19 (Pfizer–BioNTech) 
The COVID-19 pandemic has caused significant morbidity and mortality throughout the world, as well as major social, educational 
and economic disruptions. There is an urgent global need for effective and safe vaccines. On 31 December 2020, WHO listed the 
COVID-19 mRNA vaccine BNT162b2 for emergency use, making the Pfizer–BioNTech vaccine the first to receive emergency 
validation from WHO since the outbreak began a year earlier. The WHO Emergency Use Listing Procedure (EUL) is a risk-based 
procedure for assessing and listing unlicensed vaccines, therapeutics and in vitro diagnostics with the ultimate aim of expediting the 
availability of these products to people affected by a public health emergency. 
BNT162b2, an mRNA vaccine against COVID-19 developed by BioNTech and Pfizer, has been shown to have an efficacy of 
approximately 95%, based on a median follow-up of two months. The data reviewed by WHO at this time support the conclusion 
that the known and potential benefits of BNT162b2 outweigh the known and potential risks. As sufficient vaccine supply will not 
be immediately available to immunize all who could benefit from it, countries are recommended to use the WHO Prioritization 
Roadmap [4] and the WHO Values Framework [5] as guidance for their prioritization of target groups. As long as vaccine supplies 
are very limited (stage I in the WHO Prioritization Roadmap), in settings with community transmission, the Roadmap recommends 
that priority be given initially to health workers at high risk and older people with and without comorbidities. Protecting high-risk 
health workers has a threefold purpose: (i) to protect the individual health workers; (ii) to protect critical essential services during 
the COVID-19 pandemic, and (iii) to prevent onward transmission to vulnerable people. Protecting older people will have the 
greatest public health impact in terms of reducing the number of deaths. As more vaccine becomes available, additional priority 
groups should be vaccinated as outlined in the WHO Prioritization Roadmap [4], taking into account national epidemiological data 
and other relevant considerations.  
 
Intended use 
Persons aged 16 years and above.  




The recommended schedule is two doses (30 µg, 0.3 ml each) given intramuscularly into the deltoid muscle. An interval of 21–28 
days between the doses is recommended. If the second dose is inadvertently administered less than 21 days after the first, the dose 
does not need to be repeated. If administration of the second dose is inadvertently delayed it should be given as soon as possible 
thereafter, according to the manufacturer’s instructions. It is currently recommended that individuals receive no more than two doses 
in total. 
  
Considerations for deferring the second dose 
WHO acknowledges that a number of countries face exceptional circumstances of vaccine supply constraints combined with a high 
disease burden. Some countries have therefore considered delaying the administration of the second dose to allow for a higher initial 
coverage. This is based on the observation that efficacy has been shown to start from day 12 after the first dose and reached about 
89% between days 14 and 21, at the time when the second dose was given. No data on longer term efficacy for a single dose of the 
mRNA vaccine BNT162b2 currently exist, as the trial participants received 2 doses with an interval between doses in the trial 
ranging from 19 to 42 days. Of note, neutralizing antibody responses are modest after the first dose and increase substantially after 
the second dose.  
Countries experiencing exceptional epidemiological circumstances may consider delaying for a short period the administration of 
the second dose as a pragmatic approach to maximizing the number of individuals benefiting from a first dose while vaccine supply 
continues to increase. WHO’s recommendation at present is that the interval between doses may be extended up to 42 days (6 
weeks), on the basis of currently available clinical trial data. Should additional data become available on longer intervals between 
doses, revision of this recommendation will be considered. Countries should ensure that any such programme adjustments to dose 
intervals do not affect the likelihood of receiving the second dose. 
 
Booster doses 
There is currently no evidence on the need for a booster dose or booster doses of the vaccine after the current two-dose vaccine 
series is complete. The need for and timing of booster doses will be evaluated as further data accumulate. 
 
Interchangeability with other vaccines 
No data are available on the interchangeability of this vaccine with other mRNA vaccines or other COVID-19 vaccine platforms. It 
is currently recommended that the same product should be used for both doses. If different COVID-19 vaccine products are 
inadvertently administered in the two doses, no additional doses of either vaccine are recommended at this time. Recommendations 
may be updated as further information becomes available on interchangeability.  
 
Co-administration with other vaccines 
There should be a minimum interval of 14 days between administration of this vaccine and any other vaccine against other conditions, 
until data on co-administration with other vaccines become available.  
 
Contraindications 
A history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine is a contraindication to vaccination. In 
particular, BNT162b2 should not be administered to individuals with a known history of severe allergic reaction to polyethylene 
glycol (PEG) or related molecules as PEG is a component of the vaccine.  
 
Precautions 
Anaphylactic reactions after administration of BNT162b2 vaccine have been reported outside of clinical trials. A history of any 
immediate allergic reaction to any other vaccine or injectable therapy (i.e. intramuscular, intravenous, or subcutaneous vaccines or 
therapies) is considered as a precaution but not a contraindication to vaccination. For such persons, a risk assessment should be 
conducted to determine the type and severity of reaction and the reliability of the information. Such individuals may still receive 
vaccination, but they should be counselled about the risks of developing a severe allergic reaction and the risks should be weighed 
against the benefits of vaccination. Such persons should be observed for 30 minutes after vaccination in health care settings where 
anaphylaxis can be immediately treated.  
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In general, persons with an immediate allergic reaction to the first dose should not receive additional doses. For the purposes of this 
guidance, an immediate allergic reaction to a vaccine or medication is defined as any hypersensitivity-related signs or symptoms, 
such as anaphylaxis, urticaria, angioedema, respiratory distress (e.g. wheezing, stridor), that occur within hours of administration. 
However, subject to individual risk-benefit assessment, specialist services for immunization may allow BNT162b2 to be provided 
under close medical supervision if it is the only available option for persons at high risk of severe COVID-19.  
As a small number of anaphylactic reactions have also been reported in vaccinees without a history of severe allergic reactions, 
WHO recommends that BNT162b2 vaccine should be administered only in settings where anaphylaxis can be treated. Until more 
data and insights are available with regard to severe allergic reactions to BNT162b2 vaccination, all vaccinees should be observed 
for at least 15 minutes after vaccination.  
Food, contact, or seasonal allergies are not considered a precaution. The vial stoppers are not made with natural rubber latex, and 
there is no contraindication or precaution to vaccination for persons with a latex allergy. In addition, as BNT162b2 does not contain 
eggs or gelatin, there is no contraindication or precaution to vaccination for persons with allergies to these substances. 
Anyone with an acute febrile illness (body temperature over 38.5 ºC) should postpone vaccination until they are afebrile.  
 
Vaccination of specific populations 
Populations for which supportive data are available from phase 2/3 clinical trials  
Older people 
The risk of severe COVID-19 and death increases steeply with age. Data from the phase 3 trial indicate that the efficacy and safety 
of the vaccine are comparable across all age groups (above the age of 16). Vaccination is recommended for older persons. 
 
Persons with comorbidities  
Certain comorbidities have been identified as increasing the risk of severe COVID-19 disease and death. Phase 2/3 clinical trials 
have demonstrated that the vaccine has similar safety and efficacy profiles in persons with various underlying medical conditions, 
including those that place them at increased risk for severe COVID-19. The comorbidities studied in phase 2/3 clinical trials include 
hypertension; diabetes; asthma; and pulmonary, liver and kidney disease; as well as chronic (stable and controlled) infection with 
human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV). Vaccination is recommended for 
persons with comorbidities that have been identified as increasing the risk of severe COVID-19. 
 
Populations for which limited or no data exist from phase 2/3 clinical trials 
Persons above 85 years of age 
Persons above the age of 85 years and very frail older persons were not included in the clinical trials. However, the safety and 
immunogenicity data obtained in a large subset of older people with and without comorbidities suggest that the benefits of 
vaccination outweigh the potential risks. Vaccination is recommended for older persons without an upper age limit.  
 
Children and adolescents below the age of 16 years 
There are currently no efficacy or safety data for children or adolescents below the age of 16 years. Until such data are available, 
individuals below 16 years of age should not be vaccinated.  
 
Pregnant women 
Pregnant women are at higher risk of severe COVID-19 compared to women of child-bearing age who are not pregnant, and COVID-
19 has been associated with an increased risk of preterm birth. The available data on BNT162b2 vaccination of pregnant women 
are insufficient to assess vaccine efficacy or vaccine-associated risks in pregnancy. However, it should be noted that the BNT162b2 
vaccine is not a live virus vaccine, the mRNA does not enter the nucleus of the cell and is degraded quickly.  
Developmental and reproductive toxicology (DART) studies in animals have not shown harmful effects in pregnancy. Further 
studies are planned in pregnant women in the coming months. As data from these studies become available, recommendations on 
vaccination will be updated accordingly. In the interim, WHO recommends not to use BNT162b2 in pregnancy, unless the benefit 
of vaccinating a pregnant woman outweighs the potential vaccine risks, such as in health workers at high risk of exposure and 
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pregnant women with comorbidities placing them in a high-risk group for severe COVID-19. Information and, if possible, 
counselling on the lack of safety and efficacy data for pregnant women should be provided. WHO does not recommend pregnancy 
testing prior to vaccination. 
 
Lactating women 
Breastfeeding offers substantial health benefits to lactating women and their breastfed children. Vaccine efficacy is expected to be 
similar in lactating women as in other adults. However, there are no data on the safety of COVID-19 vaccines in lactating women 
or on the effects of mRNA vaccines on breastfed children. As the BNT162b2 vaccine is not a live virus vaccine and the mRNA does 
not enter the nucleus of the cell and is degraded quickly, it is biologically and clinically unlikely to pose a risk to the breastfeeding 
child. On the basis of these considerations, a lactating woman who is part of a group recommended for vaccination, e.g. health 
workers, should be offered vaccination on an equivalent basis. WHO does not recommend discontinuing breastfeeding after 
vaccination.  
 
Persons living with HIV 
Persons living with HIV may be at higher risk of severe COVID-19. Among the phase 2/3 clinical trial participants with well 
controlled HIV, there were no reported differences in safety signals. HIV-positive persons who are well controlled on highly active 
antiretroviral therapy and are part of a group recommended for vaccination can be vaccinated. Available data on administration of 
the vaccine are currently insufficient to allow assessment of vaccine efficacy or safety for persons living with HIV who are not well 
controlled on therapy. It is possible that the immune response to the vaccine may be reduced, which may alter its effectiveness. In 
the interim, given that the vaccine is not a live virus, persons living with HIV who are part of a group recommended for vaccination 
may be vaccinated. Information and, where possible, counselling about vaccine safety and efficacy profiles in immunocompromised 
persons should be provided to inform individual benefit–risk assessment. It is not necessary to test for HIV infection prior to vaccine 
administration.  
 
Immunocompromised persons  
Immunocompromised persons are at higher risk of severe COVID-19. Available data are currently insufficient to assess vaccine 
efficacy or vaccine-associated risks in severely immunocompromised persons. It is possible that the immune response to the vaccine 
may be reduced, which may alter its effectiveness. In the interim, given that the vaccine is not a live virus, immunocompromised 
persons who are part of a group recommended for vaccination may be vaccinated. Information and, where possible, counselling 
about vaccine safety and efficacy profiles in immunocompromised persons should be provided to inform individual benefit–risk 
assessment. 
 
Persons with autoimmune conditions 
No data are currently available on the safety and efficacy of BNT162b2 in persons with autoimmune conditions, although these 
persons were eligible for enrolment in the clinical trials. Persons with autoimmune conditions who have no contraindications to 
vaccination may be vaccinated. 
 
Persons with a history of Bell’s palsy 
Cases of Bell’s palsy were reported following vaccination in participants in the Pfizer-BioNTech clinical trials. However, there is 
currently no conclusive evidence that these cases were causally related to vaccination. Post-authorization safety surveillance will be 
important to assess any possible causal association. In the absence of such evidence, persons with a history of Bell’s palsy may 
receive BNT162b2 unless they have a contraindication to vaccination. 
 
Persons who have previously had SARS-CoV-2 infection 
Vaccination may be offered regardless of a person’s history of symptomatic or asymptomatic SARS-CoV-2 infection. Viral or 
serological testing for prior infection is not recommended for the purpose of decision-making about vaccination. Available data 
from the phase 2/3 trials indicate that BNT162b2 is safe in people with evidence of prior SARS-CoV-2 infection. The added 
protection of vaccinating previously infected individuals is yet to be established. Despite the potential for reinfection, currently 
available data indicate that symptomatic reinfection within 6 months after an initial infection is rare. Thus, persons with PCR-
confirmed SARS-CoV-2 infection in the preceding 6 months may delay vaccination until near the end of this period. When more 
data on duration of immunity after natural infection become available, the length of this time period may be revised. 
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Persons with current acute COVID-19 
Vaccination of persons with acute symptomatic SARS-CoV-2 should be deferred until they have recovered from acute illness and 
the criteria for discontinuation of isolation have been met. There are no data to support a recommendation of a minimal interval 
between onset of symptoms and vaccination.  
 
Persons who previously received passive antibody therapy for COVID-19 
Currently there are no data on the safety or efficacy of vaccination in persons who received monoclonal antibodies or convalescent 
plasma as part of COVID-19 treatment. Hence, as a precautionary measure, vaccination should be deferred for at least 90 days to 
avoid interference of the antibody treatment with vaccine-induced immune responses.  
 
Special settings 
Persons in settings such as refugee and detention camps, prisons, slums, and other settings with high population densities, where 
physical distancing is not implementable, should be prioritized for vaccination as outlined in the WHO Prioritization Roadmap [4], 
taking into account national epidemiological data, vaccine supply and other relevant considerations.  
As noted in the WHO Prioritization Roadmap, national programmes should give special consideration to groups that are 
disproportionately affected by COVID-19 or that face health inequities as a result of social or structural inequities. Such groups 
should be identified, barriers to vaccination should be addressed, and programmes should be developed to enable equitable access 
to vaccines.  
In the current period of very limited vaccine supply, preferential vaccination of international travelers would counter the principle 
of equity. Because of this and the lack of evidence on whether vaccination reduces the risk of transmission, WHO currently does 
not recommend COVID-19 vaccination of travelers (unless they are also part of a high-risk group or in epidemiological settings 




Prior receipt of the vaccine will not affect the results of SARS-CoV-2 nucleic acid amplification or antigen tests for diagnosis of 
acute/current SARS-CoV-2 infection. However, it is important to note that currently available antibody tests for SARS-CoV-2 assess 
levels of IgM and/or IgG to the spike or the nucleocapsid protein. The vaccine contains mRNA that encodes the spike protein; thus, 
a positive test for spike protein IgM or IgG could indicate either prior infection or prior vaccination. To evaluate for evidence of 
prior infection in an individual who has received the BNT162b2 vaccine, a test that specifically evaluates IgM or IgG to the 
nucleocapsid protein should be used. A positive nucleocapsid protein-based assay indicates prior infection. Antibody testing is not 
currently recommended to assess immunity to COVID-19 following BNT162b2 vaccination. 
 
Role of vaccines among other preventive measures 
As there is not yet any evidence of an effect of the vaccine on transmission, non-pharmaceutical interventions must continue, 
including use of face masks, physical distancing, handwashing and other measures based on the epidemiology of SARS-CoV-2 in 
particular settings. Government advice on non-pharmaceutical interventions should continue to be followed by vaccinated 
individuals, as well as those who have not yet been vaccinated. This advice will be updated as information on the impact of 
vaccination on virus transmission and indirect protection in the community is assessed.  
 
Community engagement, effective communication, and legitimacy 
Community engagement and effective communication (including risk communication) are essential to the success of COVID-19 
vaccination programmes. Prioritization decisions should be made through transparent processes that are based on shared values, the 
best available scientific evidence, and appropriate representation and input by affected parties. Furthermore, communication about 
the mechanism of action of mRNA vaccines, and efficacy and safety data derived from clinical trials and post-marketing studies, 
needs to be strengthened. Strategies should include: (1) culturally acceptable and linguistically accessible communications regarding 
COVID-19 vaccination made freely available; (2) active community engagement and involvement of community opinion leaders 
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and trusted voices to improve awareness and understanding of such communications, and (3) inclusion of diverse and affected 
stakeholder opinions in decision-making. Such efforts are especially important in subpopulations who may be unfamiliar with or 
distrustful of health care systems and immunization. 
 
Vaccination logistics  
The BNT162b2 vaccine currently requires ultra-cold-chain distribution and storage conditions that will be challenging in many 
country settings. When assessing the feasibility of deploying BNT162b2, immunization programmes should consider the cold-chain 
requirements, the current minimum number of doses per shipment, the need to administer a whole batch of vaccine within a short 
time frame after removal from cold storage, and the need to ensure bundling with an adequate independent supply of the correct 
diluent. Conditions must be met to avoid exposure of vials to sunlight and ultraviolet light 
When scheduling vaccination for occupational groups, e.g. health workers, consideration should be given to the reactogenicity 
profile of BNT162b2 observed in clinical trials, leading to time off work in the 24-48 hours following vaccination. 
Appropriate medical treatment to manage anaphylaxis must be immediately available. Hence, this vaccine should only be 
administered in settings with the necessary resources and trained health workers, and in settings that allow for at least 15 minutes 
of post-vaccination observation. 
In considering the programme implications of implementing these recommendations, particular attention should be given to equity, 
including the feasibility, acceptability, and effectiveness of the programme in resource-constrained settings (for example, how to 
ensure ultra-cold chain storage and the need to be able to provide treatment for anaphylaxis). 
 
Recommendations on addressing current knowledge gaps through further research  
In order to confirm the safety profile demonstrated in the clinical trials in the short term, active surveillance of large numbers of 
vaccinated individuals is necessary in the general population studied for a longer duration, as well as of specific at-risk 
subpopulations. It is essential for Pfizer–BioNTech and vaccination providers to report the following to adverse event reporting 
systems in countries: all vaccine administration errors, serious adverse events, cases of multisystem inflammatory syndrome (MIS) 
following vaccination, anaphylaxis and other serious allergic reactions, Bell`s palsy, and cases of COVID-19 following vaccination 
that result in hospitalization or death. 
WHO recommends the following research and post-authorization monitoring activities:  
• vaccine effectiveness over time; 
• ongoing collection of safety data in vaccine recipients;  
• surveillance for COVID-19 among vaccinated individuals, looking for vaccine-induced enhanced disease (possibly as 
vaccine-induced antibody levels decline); 
• safety data from inadvertently vaccinated pregnant women during trials and post-authorization; 
• safety data from pregnant women who receive vaccine because they are members of prioritized groups, e.g. health workers; 
• prospective studies on the safety of BNT162b2 in pregnant women; 
• impact on infants of vaccination of breastfeeding mothers; 
• safety data on vaccination in immunocompromised persons, including persons living with HIV and persons with 
autoimmune disease; 
• impact of delayed second dose as currently implemented by certain countries; 
• clinical trials on the efficacy and safety of vaccination of children below the age of 16 years; 
• immunogenicity and safety studies of co-administration with other vaccines, including influenza and pneumococcal 
vaccines, to adults and older persons; 
• studies to determine how protection changes with time since vaccination and whether protection can be prolonged by 
booster doses; 
• studies to demonstrate whether this vaccine reduces SARS-CoV-2 transmission and viral shedding; 
• stability of vaccine under alternative cold-chain distribution and storage conditions; 
• effectiveness of the proposed strategies for the prevention and management of anaphylactic reactions; 
• interchangeability and “mix and match” studies within and across COVID-19 vaccine platforms; 
• global surveillance of virus evolution and the impact of virus mutants on vaccine effectiveness to support possible update 
of vaccines if needed; 
• head-to-head studies with other vaccines on extent and duration of immunity using standardized neutralization assays and 
mucosal immunity assays. 
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WHO continues to monitor the situation closely for any changes that may affect this interim guidance. Should any factors change, 
WHO will issue a further update. Otherwise, this interim guidance document will expire 2 years after the date of publication.
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